1. |
Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis[J]. Prog Retin Eye Res, 2015, 48: 82-118. DOI: 10.1016/j.preteyeres.2015.05.003.
|
2. |
Karadimas P, Kapetanios A, Bouzas EA. Central serous chorioretinopathy after local application of glucocorticoids for skin disorders[J]. Arch Ophthalmol, 2004, 122(5): 784-786. DOI: 10.1001/archopht.122.5.784.
|
3. |
Fernandez CF, Mendoza AJ, Arevalo JF. Central serous chorioretinopathy associated with topical dermal corticosteroids[J]. Retina, 2004, 24(3): 471-474. DOI: 10.1097/00006982-200406000-00027.
|
4. |
Ezra N, Taban M, Behroozan D. Central serous chorioretinopathy associated with topical corticosteroids in a patient with psoriasis[J]. J Drugs Dermatol, 2011, 10(8): 918-921.
|
5. |
Chan LY, Adam RS, Adam DN. Localized topical steroid use and central serous retinopathy[J]. J Dermatolog Treat, 2016, 27(5): 425-426. DOI: 10.3109/09546634.2015.1136049.
|
6. |
Nicholson B, Noble J, Forooghian F, et al. Central serous chorioretinopathy: update on pathophysiology and treatment[J]. Surv Ophthalmol, 2013, 58(2): 103-126. DOI: 10.1016/j.survophthal.2012.07.004.
|
7. |
Liu B, Deng T, Zhang J. Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis[J]. Retina, 2016, 36(1): 9-19. DOI: 10.1097/IAE.0000000000000837.
|
8. |
Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids[J]. J Am Acad Dermatol, 2006, 54(1): 1-18. DOI: 10.1016/j.jaad.2005.01.010.
|
9. |
Turpeinen M, Lehtokoski-Lehtiniemi E, Leisti S, et al. Percutaneous absorption of hydrocortisone during and after the acute phase of dermatitis in children[J]. Pediatr Dermatol, 1988, 5(4): 276-279. DOI: 10.1111/j.1525-1470.1988.tb00904.x.
|
10. |
du Vivier A. Tachyphylaxis to topically applied steroids[J]. Arch Dermatol, 1976, 112(9): 1245-1248. DOI: 10.1001/archderm.1976.01630330015002.
|
11. |
Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment[J]. Eye (Lond), 2010, 24(12): 1743-1756. DOI: 10.1038/eye.2010.130.
|
12. |
Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study[J]. Retina, 2013, 33(10): 2096-2102. DOI: 10.1097/IAE.0b013e318297a07a.
|
13. |
El Zaoui I, Behar-Cohen F, Torriglia A. Glucocorticoids exert direct toxicity on microvasculature: analysis of cell death mechanisms[J]. Toxicol Sci, 2015, 143(2): 441-453. DOI: 10.1093/toxsci/kfu243.
|